Difference between revisions of "Ixabepilone (Ixempra)"
Jump to navigation
Jump to search
(updated content) |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]") |
||
| (23 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.<ref name="insert">[ | + | Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf Ixabepilone (Ixempra) package insert]</ref><ref>[[:File:Ixabepilone.pdf | Ixabepilone (Ixempra) package insert (locally hosted backup)]]</ref><ref>[http://www.ixempra.com/ Ixempra manufacturer's site]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf#page=31 Ixabepilone (Ixempra) patient drug information]<ref>[http://packageinserts.bms.com/pi/pi_ixempra.pdf#page=8 Ixabepilone (Ixempra) patient drug information]</ref> |
| − | *[ | + | *[https://chemocare.com/druginfo/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/ixabepilone.aspx Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2007-10-16: Initial approval in combination with [[Capecitabine (Xeloda) | capecitabine]] for the treatment of metastatic or locally advanced [[Breast cancer | breast cancer]] in patients after failure of an [[:Category:Anthracyclines|anthracycline]] and a [[:Category:Taxanes|taxane]]. ''(Based on CA163-046 & CA163-048)'' | ||
| + | *2007-10-16: Initial approval as monotherapy for the treatment of metastatic or locally advanced [[Breast cancer | breast cancer]] in patients after failure of an [[:Category:Anthracyclines|anthracycline]], a [[:Category:Taxanes|taxane]], and [[Capecitabine (Xeloda) | capecitabine]]. ''(Based on CA163-081)'' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' BMS-247550 | ||
| + | *'''Generic names:''' azaepothilone B, epothilone B lactam | ||
| + | *'''Brand name:''' Ixempra | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Intravenous medications]] |
| − | [[Category:Irritant | + | [[Category:Irritant]] |
| + | |||
| + | [[Category:Epothilones]] | ||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
| + | |||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2007]] | ||
Revision as of 01:05, 27 June 2024
General information
Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ixabepilone (Ixempra) patient drug information[4]
- Ixabepilone (Ixempra) patient drug information (Chemocare)[5]
- Ixabepilone (Ixempra) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 2007-10-16: Initial approval in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. (Based on CA163-046 & CA163-048)
- 2007-10-16: Initial approval as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. (Based on CA163-081)
Also known as
- Code name: BMS-247550
- Generic names: azaepothilone B, epothilone B lactam
- Brand name: Ixempra
References
- ↑ 1.0 1.1 Ixabepilone (Ixempra) package insert
- ↑ Ixabepilone (Ixempra) package insert (locally hosted backup)
- ↑ Ixempra manufacturer's site
- ↑ Ixabepilone (Ixempra) patient drug information
- ↑ Ixabepilone (Ixempra) patient drug information (Chemocare)
- ↑ Ixabepilone (Ixempra) patient drug information (UpToDate)